KR20240099290A - Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법 - Google Patents

Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법 Download PDF

Info

Publication number
KR20240099290A
KR20240099290A KR1020247016221A KR20247016221A KR20240099290A KR 20240099290 A KR20240099290 A KR 20240099290A KR 1020247016221 A KR1020247016221 A KR 1020247016221A KR 20247016221 A KR20247016221 A KR 20247016221A KR 20240099290 A KR20240099290 A KR 20240099290A
Authority
KR
South Korea
Prior art keywords
antibody
subject
antigen
dose
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016221A
Other languages
English (en)
Korean (ko)
Inventor
엘리자베스 로스
존 오말리
나이미쉬 파텔
헤리베르트 슈타우딩거
아시시 반살
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Publication of KR20240099290A publication Critical patent/KR20240099290A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247016221A 2021-10-20 2022-10-19 Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법 Pending KR20240099290A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163257876P 2021-10-20 2021-10-20
US63/257,876 2021-10-20
US202263300492P 2022-01-18 2022-01-18
US63/300,492 2022-01-18
EP22315048 2022-03-04
EP22315048.3 2022-03-04
PCT/US2022/078341 WO2023069976A1 (en) 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
KR20240099290A true KR20240099290A (ko) 2024-06-28

Family

ID=84329583

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016221A Pending KR20240099290A (ko) 2021-10-20 2022-10-19 Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법

Country Status (10)

Country Link
US (1) US20230183362A1 (https=)
EP (1) EP4419557A1 (https=)
JP (1) JP2024539148A (https=)
KR (1) KR20240099290A (https=)
CN (1) CN119137149A (https=)
AU (1) AU2022369296A1 (https=)
CA (1) CA3235380A1 (https=)
IL (1) IL312187A (https=)
MX (1) MX2024004762A (https=)
WO (1) WO2023069976A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
IL293487A (en) * 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
US20230374144A1 (en) 2020-09-10 2023-11-23 Staidson (Beijing) Biopharmaceutical Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof

Also Published As

Publication number Publication date
US20230183362A1 (en) 2023-06-15
MX2024004762A (es) 2024-05-08
JP2024539148A (ja) 2024-10-28
WO2023069976A1 (en) 2023-04-27
EP4419557A1 (en) 2024-08-28
IL312187A (en) 2024-06-01
CN119137149A (zh) 2024-12-13
AU2022369296A1 (en) 2024-05-30
CA3235380A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US20210322546A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2025205430A1 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
US20230146317A1 (en) Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TW202432598A (zh) 藉由投予il-4r拮抗劑治療手足皮膚炎的方法
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
KR20250160361A (ko) Il-4r 길항제를 투여하여 만성 폐쇄성 폐 질환(copd)을 치료하는 방법
JP2019069987A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法
US20250388685A1 (en) Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2026059949A1 (en) Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
JP2025528456A (ja) Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40023224A (en) Methods for treating nasal polyposis by administering an il-4r antagonist
HK40023224B (en) Methods for treating nasal polyposis by administering an il-4r antagonist
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
HK1222567B (en) Methods for treating nasal polyposis by administering an il-4r antagonist
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TW201907950A (zh) 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000